Galectin Therapeutics Inc.’s GALT share price has dipped by 20.00%, which has investors questioning if this is right time to buy.

Analysts at HC Wainwright issued their FY2029 EPS estimates for Galectin Therapeutics in a report released on Wednesday, April 2nd. HC Wainwright analyst E. Arce expects that the company will post ...

NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results ...

Galectin Therapeutics Inc. (NASDAQ:GALT – Free Report) – HC Wainwright lifted their Q2 2025 earnings per share (EPS) estimates for shares of Galectin Therapeutics in a research note issued to ...

Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics (GALT), said “In the U.S. approximately 5 million adults are ...

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs ...

NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and ...